X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Elder Pharma with Dr. Reddys - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ELDER PHARMA vs DR. REDDYS LAB - Comparison Results

DR. REDDYS LAB 
   Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the value chain. While the global generics business accounted for 69% of total revenues in FY12, the PSAI business (Pharma Services and Active Ingredients - PSAI) con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ELDER PHARMA DR. REDDYS LAB ELDER PHARMA/
DR. REDDYS LAB
 
P/E (TTM) x -0.2 31.5 - View Chart
P/BV x 0.1 3.4 3.0% View Chart
Dividend Yield % 0.0 0.8 -  

Financials

 ELDER PHARMA   DR. REDDYS LAB
EQUITY SHARE DATA
    ELDER PHARMA
Jun-14
DR. REDDYS LAB
Mar-18
ELDER PHARMA/
DR. REDDYS LAB
5-Yr Chart
Click to enlarge
High Rs3802,788 13.6%   
Low Rs1881,902 9.9%   
Sales per share (Unadj.) Rs491.2860.8 57.1%  
Earnings per share (Unadj.) Rs-3.257.1 -5.6%  
Cash flow per share (Unadj.) Rs14.4122.0 11.8%  
Dividends per share (Unadj.) Rs020.00 0.0%  
Dividend yield (eoy) %00.9 0.0%  
Book value per share (Unadj.) Rs376.5757.7 49.7%  
Shares outstanding (eoy) m20.54165.91 12.4%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x0.62.7 21.2%   
Avg P/E ratio x-89.341.1 -217.2%  
P/CF ratio (eoy) x19.719.2 102.5%  
Price / Book Value ratio x0.83.1 24.4%  
Dividend payout %035.0 0.0%   
Avg Mkt Cap Rs m5,833389,034 1.5%   
No. of employees `000NA23.5 0.0%   
Total wages/salary Rs m2,17932,149 6.8%   
Avg. sales/employee Rs ThNM6,070.8-  
Avg. wages/employee Rs ThNM1,366.6-  
Avg. net profit/employee Rs ThNM402.5-  
INCOME DATA
Net Sales Rs m10,089142,810 7.1%  
Other income Rs m2571,552 16.5%   
Total revenues Rs m10,346144,362 7.2%   
Gross profit Rs m-79223,512 -3.4%  
Depreciation Rs m36110,772 3.4%   
Interest Rs m2,756788 349.8%   
Profit before tax Rs m-3,65313,504 -27.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m0344 0.0%   
Extraordinary Inc (Exp) Rs m3,7130-   
Tax Rs m1254,380 2.9%   
Profit after tax Rs m-659,468 -0.7%  
Gross profit margin %-7.816.5 -47.7%  
Effective tax rate %-3.432.4 -10.6%   
Net profit margin %-0.66.6 -9.8%  
BALANCE SHEET DATA
Current assets Rs m9,240104,984 8.8%   
Current liabilities Rs m9,99868,938 14.5%   
Net working cap to sales %-7.525.2 -29.8%  
Current ratio x0.91.5 60.7%  
Inventory Days Days4674 62.3%  
Debtors Days Days60104 57.9%  
Net fixed assets Rs m10,124104,385 9.7%   
Share capital Rs m206830 24.8%   
"Free" reserves Rs m5,582124,886 4.5%   
Net worth Rs m7,734125,716 6.2%   
Long term debt Rs m4,88925,089 19.5%   
Total assets Rs m22,882225,443 10.1%  
Interest coverage x-0.318.1 -1.8%   
Debt to equity ratio x0.60.2 316.8%  
Sales to assets ratio x0.40.6 69.6%   
Return on assets %11.84.5 258.5%  
Return on equity %-0.87.5 -11.2%  
Return on capital %22.39.7 229.9%  
Exports to sales %3.00-   
Imports to sales %0.40-   
Exports (fob) Rs m307NA-   
Imports (cif) Rs m43NA-   
Fx inflow Rs m30772,623 0.4%   
Fx outflow Rs m12518,916 0.7%   
Net fx Rs m18153,707 0.3%   
CASH FLOW
From Operations Rs m11,75418,030 65.2%  
From Investments Rs m-561-14,883 3.8%  
From Financial Activity Rs m-6,762-4,440 152.3%  
Net Cashflow Rs m4,432-1,236 -358.6%  

Share Holding

Indian Promoters % 39.6 25.5 155.3%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 7.5 5.4 138.9%  
FIIs % 16.8 35.3 47.6%  
ADR/GDR % 0.0 18.5 -  
Free float % 36.1 15.3 235.9%  
Shareholders   16,479 75,885 21.7%  
Pledged promoter(s) holding % 77.6 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ELDER PHARMA With:   AUROBINDO PHARMA  ORCHID PHARMA LTD  NOVARTIS  J.B.CHEMICALS  MERCK LTD  

Compare ELDER PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Slumps Over 275 Points; Realty and Banking Stocks Witness Selling(Closing)

After trading on a volatile note throughout the day, share markets in India witnessed selling pressure during the closing hours and ended the day in red.

Related Views on News

DR. REDDYS LAB at 52 Week High; BSE 500 Index Up 1.0% (Market Updates)

Sep 21, 2018 | Updated on Sep 21, 2018

DR. REDDYS LAB share price has hit a 52-week high. It is presently trading at Rs 2,667. BSE 500 Index is up by 0.8% at 15,275. Within the BSE 500, DR. REDDYS LAB (up 2.4%) and SCHNEIDER ELECTRIC INFRA (up 5.9%) are among the top gainers, while top losers are YES BANK and GODREJ PROPERTIES.

DR. REDDYS LAB Announces Quarterly Results (1QFY19); Net Profit Up 614.9% (Quarterly Result Update)

Jul 27, 2018 | Updated on Jul 27, 2018

For the quarter ended June 2018, DR. REDDYS LAB has posted a net profit of Rs 5 bn (up 614.9% YoY). Sales on the other hand came in at Rs 37 bn (up 12.1% YoY). Read on for a complete analysis of DR. REDDYS LAB's quarterly results.

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

More Views on News

Most Popular

Is It the Right Time to Buy Pharma Stocks Now?(The 5 Minute Wrapup)

Sep 12, 2018

Is the pharma sector poised for a comeback? Is the worst over? I believe so.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

Investors Are Redeeming From Equity Mutual Funds Now. Should You?(Outside View)

Sep 12, 2018

PersonalFN elucidates if you should redeem from equity mutual fund now, and the approach to follow before you decide to sell mutual funds.

Are You Blindly Investing In Equities? Read This...(Outside View)

Sep 11, 2018

PersonalFN explains how blindly investing in equities can prove hazardous to your wealth and health.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ELDER PHARMA SHARE PRICE


Sep 12, 2016 (Close)

TRACK ELDER PHARMA

  • Track your investment in ELDER PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ELDER PHARMA - SANOFI INDIA COMPARISON

COMPARE ELDER PHARMA WITH

MARKET STATS